Olema Pharmaceuticals, Inc. (OLMA)

Olema reports phase 1 data for cancer drug OP-3136

Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q1 Net Loss $0.52 a Share, vs.

The company reported earnings of -$0.52 per share, beating estimates of -$0.54 by $0.02. The company also reported revenue of $0, equaling estimates of $0 by $0.You can see Quiver Quantitative's $OLMA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.

Analyzing the Strengths, Weaknesses, Opportunities, and Threats of Olema Pharmaceuticals Inc.

Olema Pharmaceuticals, Inc. reported a loss in the first quarter of 2026, with net income of $(53.1)M, or diluted loss per share of $(0.52), versus a net loss of $(30.4)M, or $(0.36) per share in the year‑ago quarter. The company remains pre‑revenue with no product sales in the period.Financial ...